Insurance for Pets

Vetoquinol: finalizes the acquisition of Profender® and Drontal® products – Insurance for Pets

Regulatory News:

Vetoquinol (Paris: VETO) confirms the acquisition of the rights in Europe and the United Kingdom to the Profender® and Drontal® product families. This acquisition was finalized on 1er August 2020.

Vetoquinol has acquired the Profender® and Drontal® products, intellectual property, registrations and other rights currently held by Bayer AG Animal Health for Europe and the United Kingdom. Profender® and Drontal® are deworming medicines for dogs and cats, available in tablets and spot-on application.

The purchase of Profender® and Drontal® by Vetoquinol is linked to the acquisition by Elanco of Bayer AG Animal Health, which was completed on 1er August 2020.

Matthieu Frechin, CEO of Vetoquinol, declared: “ We are pleased to have completed the acquisition of the Profender® and Drontal® product lines. These two ranges fit perfectly into our strategy; they will allow us to significantly increase our market share and our visibility in the antiparasitic segment, one of our strategic therapeutic areas. On the other hand, the Profender® and Drontal® products strengthen our portfolio of Essentials, the engines of our growth. I am proud of our teams who made it possible to carry out this external growth operation, despite the complicated context that the health crisis has imposed on us.  »

Next post : Q3 2020 revenue, October 15, 2020 after market close

About Vetoquinol

Vetoquinol is a benchmark international player in animal health, present in Europe, the Americas and Asia / Pacific.

Independent and “pure player”, Vetoquinol innovates, develops and markets veterinary drugs and non-drug products intended for production animals (cattle, pigs) and companion animals (dogs, cats).

Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and the acquisitions made in areas with high potential ensure hybrid growth for the Group. As of June 30, 2020, Vetoquinol employs 2,401 people.

Vetoquinol has been listed on Euronext Paris since 2006 (mnemonic code: VETO).

To get to know the Group better: